ISSUE NO. 3 VOLUME 6 DATE: 14. JUN 2019

Centre for Cancer Biomarkers
Norwegian Centre of Excellence – University of Bergen

Norwegian Centre of Excellence
The Research Council of Norway

"CAPTURING CANCER COMPLEXITY AND CLINICAL CHALLENGES"

CCBIO Newsletter

EDITOR: eli.vidhammer@uib.no

DIRECTOR'S COMMENTS

Dear all

Thank you very much to those of you attending the successful 7th CCBIO Annual Symposium at Solstrand. We appreciate all the engagement during the meeting, and the practical help. We also had a very successful satellite symposium on Deep Tissue Profiling, with several international experts. Thanks to Sonia Gavasso for helping us in setting up this meeting.

In this issue of the Newsletter, you will find updates on a range of CCBIO activities. In particular, congratulations to Elisabeth Wik and Ragnhild Haugse for winning awards - well deserved! And take a look at the CCBIO Calendar for upcoming courses and events during the fall, and save the dates.

If you have not yet read the CCBIO Annual Report, please do so. A special thank you to Gaute Hatlem (art direction and layout) and Ingvild Festervoll Melien (photos) for outstanding work, as always!

And last but certainly not least: Many thanks to Eli Vidhammer for her excellent work as our hard-working web and newsletter editor!

I wish you all a nice summer break!

Best regards, Lars A. Akslen, Director

Programs and Research Teams

Mechanisms of Tumor-Microenvironment Interactions:
- Donald Gullberg
- Karl-Henning Kalland
- Emmet McCormack

Exploration and Validation of Cancer Biomarkers:
- Lars A. Akslen
- Jim Lorens
- Camilla Krakstad
- Daniela Costea
- Elisabeth Wik

Clinical Applications and Trial Studies:
- Bjørn Tore Gjertsen
- Oddbjørn Straume
- Line Bjørge

Health Ethics, Prioritization and Economics:
- Roger Strand
- John Cairns
- Ole Frithjof Norheim

Support resource:
Bioinformatics and Big Data
- Inge Jonassen

Centre Director:
Prof. Dr.Med Lars A. Akslen
+ 47 55 97 31 82 lars.akslen@uib.no

Administrative Leader:
Geir Olav Løken
+ 47 55 58 54 36 geir.loken@uib.no

Support for grant applications:
Yves Aubert
+47 55 58 89 69 Yves.Aubert@uib.no

All administrative officers:
link.

www.ccbio.no

WORLD LEADING CANCER EXPERTS MET AT SOLSTRAND

CCBIO's 7th Annual Symposium provided new knowledge, inspiration and excellent networking for the 200 participants at Solstrand Hotel which also this year showed off in the sunshine.

This year, topics ranged from calculating the risk of breast cancer through genetic tests, to drug development and innovation. (See program.)

And as a tradition that started last year, CCBIO also hosted a Satellite Symposium the day before at the same venue, this time on the topic Deep Tissue Profiling.

"At our satellite symposium, the significance of tissue context and topography was discussed. Such information is needed to advance the field of omics studies, through techniques such as imaging mass cytometry. The issue is location, location, location", says CCBIO Director Lars A. Akslen.

"It was a huge inspiration to be present, and I was happy to observe intense discussions and networking during this meeting. The good vibrations continued throughout the main symposium. It is a privilege to host such outstanding scientists, presenting their latest work on different topics. This soil is indeed important for our seeds to grow in an excellent way," he concludes.

One of the invited keynote speakers on the topic of innovation, Professor Omid Farokhzad at Harvard Medical School, was concerned with turning academic innovations into medical products and technologies with great impact on lives and society. He was encouraged to provide 3 tips on how to make your ideas come to life:

1. The most important thing is that you should go after solving important and big problems.
2. If you do so, usually the scientific community rewards you with a high impact publication, providing validation in a peer reviewed process.
3. Protect your innovation by filing patents before you publicly disclose your findings, and then you can get investors interested in your ideas and add the capital you need to advance your ideas and concepts further.

Read full article on the CCBIO Annual Symposium here.

















BEST OF ASCO

The ASCO American Society of Clinical Oncology's Annual Meeting which took place in Chicago May 31st to June 4th, featured a study with co-author Line Bjørge highlighted as a "Best of ASCO" presentation, considered as a study which will be of great importance in the field of gynecologic cancers.


Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.

Presented Monday, June 3, 2019

Abstract Video Slides

Authors:
Mansoor Raza Mirza, Elisabeth Avall-Lundqvist, Michael J. Birrer, Rene dePont Christensen, Gitte-Bettina Nyvang, Susanne Malander, Maarit Anttila, Theresa Louise Werner, Bente Lund, Gabriel Lindahl, Sakari Hietanen, Ulla Peen, Maria Dimoula, Henrik Roed, Anja Ør Knudsen, Louisa Boufercha, Synnove Staff, Anders Krog Vistisen, Line Bjørge, Johanna Unelma Maenpaa; NSGO and Rigshospitalet...

The study was presented at ASCO by first author Mansoor Raza Mirza, who – by the way – will be lecturing at the new CCBIO Research School Course, Clinical Trials in Cancer Research, this fall (see next page).

The study investigates the efficacy of a combination of bevacizumab (BEV) and PARP inhibitors (PARPi) as an alternative to chemotherapy as treatment in ovarian cancer. This would significantly reduce the need for exposing patients to the chemo toxins.

In the study, 97 patients with platinum-sensitive recurrent ovarian cancer were randomized to the parp inhibitor niraparib 300mg once daily or the combination of niraparib 300mg once daily and BEV 15mg/kg IV every 3 weeks until disease progression (1:1 randomization). The primary endpoint was progression-free survival (PFS).

"The first group had a progression-free survival rate of 5.5 months. The patient group receiving combination therapy had a progression-free survival rate of almost one year. The conclusion is that both treatments have a clinically relevant effect, but the combination is the best," says CCBIO Associate Investigator Line Bjørge.

"Today, only patients with recurrent disease and the gene mutation BRCA1 or BRCA2 are offered parp inhibitors," Bjørge continues. "Our study shows that patients can have effect of this treatment, regardless of whether they have the genetic deficiency," she concludes.

Read article in Dagens Medisin (in Norwegian).

INTERNATIONAL FIBROSIS CONFERENCE IN BERGEN

On May 23 and 24, 2019, the world's leading fibrosis and cancer researchers met in Bergen at an international fibrosis conference on the topic "New tools to study the fibrotic stroma".


Photo: Torstein Ravnskog

During the conference, new findings were discussed in basic research and clinical research on connective tissue cells in fibrosis and tumors. Representatives from three biotechnology companies showed their ongoing work to develop drugs that focus on limiting fibrosis and tumor growth by directly targeting stroma cells.

This was the third conference within the framework of the MOTIF project. The project is a four-year cooperation between Norway and North America, financed by Diku. This year, Professor Donald Gullberg from CCBIO and the Department of Biomedicine invited the other partners from the University of Toronto, Canada and UCSF, USA. The first MOTIF conference was held in Toronto in 2017, the second at UCSF in 2018. This year's conference was held at Hotel Terminus, Bergen.

CCBIO Seminar with Valerie Weaver

Among other, Professor Valerie Weaver from the University of California in San Francisco presented at the conference. She also gave a lecture at the CCBIO seminar series. Professor Weaver has attracted great international attention. It started with a research article in 2005, in which she used experimental systems to show that a tight connective tissue is an important factor for the growth of tumors. In 2009, these results were taken further by demonstrating that a certain type of cell surface receptors - integrins - use mechanotransduction to recognize the stiffness of the connective tissue stiffness. In breast cancer, this can stimulate tumor growth.

Both of these studies have had a major impact, and Professor Weaver is now a world-leading expert in mechanical transduction. In the CCBIO Seminar entitled "Forcing tumor risk, transformation and aggression", the importance of mechanotransduction in various aspects of tumor growth was discussed.

See also news article in På Høyden (in Norwegian).

NEW MAMMOGRAPHY TECHNOLOGY IS MORE PRECISE, BUT DOES NOT DETECT MORE CANCERS

CCBIO has published an article in collaboration with the Cancer Registry of Norway (Kreftregisteret) in the high-impact journal Lancet Oncology in the beginning of May. The trial finds that new mammography technology is not dramatically better than traditional mammography.

Illustration: Colourbox.com

This is the world's first completed randomised controlled trial on the topic, with testing of digital breast-tomosynthesis in screening. This breast imaging technology provides a near 3D view of the breast, in contrast to standard mammography, which is 2D. New and advanced technology for breast cancer screening has been highly anticipated by professionals and patient organisations. Their hope has been that tomosynthesis will detect more of the aggressive and fatal breast cancers.

The principal investigator, Solveig Hofvind from Cancer Registry of Norway, and head of BreastScreen Norway, expects the trial's results to raise some eyebrows. "We found that tomosynthesis and digital mammography detected about the same amount of breast cancers. At the same time, we had to recall fewer women screened with tomosynthesis for further examinations because of suspicious findings," says Hofvind.

Hofvind says that although the results are surprising, it is safe to screen with tomosynthesis. She points out that we need further research on tomosynthesis in screening, as there are a number of areas where additional knowledge is needed. She also highlights several promising results in the trial. Among other things, the study does not support the notion that tomosynthesis detects the "wrong kind of cancers" – the small, slowly growing cancers. Fewer recalls also means less anxiety and inconvenience among women attending the screening program, as well as lower costs for the health system.

Professor Lars A. Akslen agrees with Hofvind, and says that the results from the To-Be trial indicate that the radiologists have found the "right" cancers through the use of tomosynthesis. "The aim of mammographic screening is primarily to find the 'dangerous' breast cancers that affect the woman's prognosis. When examining the tumour characteristics of the cancers in this trial, it would seem that the radiologists have been able to do just that."

Read the publication here and full press release here.

See also the Cancer Registry's news article in Norwegian.

FACULTY INTERNATIONALIZATION PRIZE TO ELISABETH WIK

Congratulations to Associate Professor Elisabeth Wik for the Faculty of Medicine's Internationalization Prize for her work as coordinator of the CCBIO/Harvard INTPART collaboration!

The criteria for the prize are that it should stimulate and reward measures that promote increased internationalization in the study programs. Transfer value to other academic environments and study programs is emphasized. Dean Per Bakke informed about the INTPART project that it was very well received in the midway evaluation and by the Norwegian Research Council at their site visit in May.

Elisabeth herself refers to this as a team effort, but we know that the prize is highly deserved through Elisabeth's hard work and focus!

Read the Department of Clinical Medicine's nomination to the prize (in Norwegian).



Photos: Geir Olav Løken

CCBIO SPECIAL SEMINAR ON MARINE BIOPROSPECTING IN DEVELOPMENT OF NEW CANCER THERAPY

CCBIO is happy to invite to a special seminar June 18th titled ”Marine bioactive compounds as a source for new anticancer drugs” by invited speaker Jeanette Hammer Andersen, professor in marine bioprospecting and head of the natural products platform Marbio at the University of Tromsø.

Illustration: Colourbox.com

Time: Tuesday June 18th at 15:00

Place: Auditorium 4, BB-building, Jonas Lies vei 91, Bergen

Speaker: Professor Jeanette Hammer Andersen, director of Marbio at the University of Tromsø / the Arctic University of Norway.

Marbio is a high capacity analysis platform for screening and identifying unique bioactive molecules isolated from marine material. Marbio is looking for eg. enzymes and enzyme inhibitors and substances that can kill cancer cells, are immunosuppressive or immunostimulatory or inhibit the growth of bacteria and viruses.

Abstract:
The success of natural products in drug discovery is unparalleled, more than 60 % of the new chemical entities introduced into the clinic originated from, or were inspired by, natural products. Even so, many pharmaceutical companies turned away from natural products as a source of lead compounds, due to the perception that natural products are both difficult to access and to work with. As the marine environment and its organisms have become more accessible over the last decades, it is expected that the ocean will be the next great source of novel chemistry. The rate of new marine natural products discovered is increasing every year.

Marbio, UiT explore Arctic and sub-Arctic marine organisms, searching for compounds with activities against cancer, bacteria and diabetes as well as compounds with immunomodulatory and antioxidative effects. Our screening campaign has been based on a classic bioassay-guided fractionation approach. We are screening a unique collection of cold-water invertebrates and marine microorganisms, and we have identified several novel bioactive structures in the collection. The presentation will give an overview of the workflow in Marbio and some of our results from the anticancer screening program.

Chairperson: Professor Bjørn Tore Gjertsen

MAKING A SEMINAR MEMORABLE

CCBIO hosted May 15-16 a seminar in scientific writing, the same course which was first run in December 2017. It was a great success then, and so it was now as well for the 85 participants. Lecturers taught among other in how to make a manuscript memorable, making the seminar memorable in the process.



Photos: Elisabeth Wik and Christine Møller

Lecturers were Christine Møller, experienced lecturer in medical and scientific writing and assistant editor of APMIS, and Randy Watnick, assistant professor at the Vascular Biology Program, Harvard Medical School. The seminar was organized as part of the in the CCBIO/Harvard INTPART collaboration, and coordinated by Elisabeth Wik. Program is available here.

The article from last time still applies, as we also this time could benefit from British humor, an American oracle and useful tips!

The seminar is scheduled next time in 2021.

MATRIX BIOLOGY COURSE WITH INTERNATIONAL TOP SPEAKERS SUCCESSFULLY COMPLETED

The week-long Matrix Biology Course BMED904 was held for 4th time June 3-7 with 12 signed up attendees, including students from France and Finland. The course in its current form is a joint venture between the research school at IBM and CCBIO with Professors Marion Kusche-Gullberg and Donald Gullberg as organizers.

The participants were updated on the the latest developments in the matrix biology field including novel roles of ECM molecules, such as collagens, integrins, proteoglycans and recent developments in matrix molecule therapeutics. To mention a few of the excellent lectures: John Couchman from BRIC, University of Copenhagen gave accounts on the role of the cell surface proteoglycans in cell adhesive interactions and as regulators of calcium channels. Kalle Sippilä from Fiona Watts laboratory in London talked about fibroblasts heterogeneity and use of lineage tracing to define subsets of fibroblasts. A highlight in the course was the lecture by UCSF Associate Professor MD Joanna Philips on the brain matrix and her CCBIO seminar on the topic "GBM heterogeneity and extracellular regulation of oncogenic signaling". The inspiring seminar focused on the role of heparan sulphate proteoglycans as co-receptors in kinase mediated signaling in glioblastoma.

Photos: Donald Gullberg

BMED904 will be given next time in June 2021.

COMING CCBIO RESEARCH SCHOOL COURSES

Now that the spring term is ending, we can focus on the fall term courses, including a brand new course!

Clinical Trials in Cancer Research

Line Bjørge and Hani Gabra are responsible for a brand new course, titled "Clinical Trials in Cancer Research". The course is designed to prepare the participants to conduct clinical trials in humans. The modules included will be based on the ICH_GCP, and the participants will receive a certificate in Good Clinical Practice on completion of the course.


Illustration: www.colourbox.com

The course will consist of 6 different modules, covering:

- General principles
- Operations
- Formalities
- Regulations
- Success factors
- Clinical trials in the future

When: October 3 and 4, 2019
Read more here.

Wonder when the other CCBIO courses are scheduled? Then see this page.

CCBIO903 Cancer research: Ethical, economic and social aspects

The course focuses on ethical, economical and societal aspects of cancer and cancer research and aims to equip PhD candidates with tools for systematic reflection on their own and related research as well as methods for assessing the cost benefit of health measures and methods of treatment.

John Cairns, Roger Strand and Anne Blanchard Bremer are responsible for the course. The course provides 5 ECTS.

When: December 9-13 2019 and January 6-9 2020.

Read more here.


Illustration: Lightspring/Shutterstock

PHARMACY GRANT TO CCBIO PHD FELLOW

Congratulations to CCBIO PhD candidate Ragnhild Haugse with the 150.000 NOK grant from the Pharmacist Morten Nyegaard and wife Katrine Nyegaards Grant! Ragnhild is in Emmet McCormack's group, with her PhD work focusing on increased drug delivery and therapeutic efficacy of cancer therapy by the use of ultrasound and microbubbles (sonoporation).

Leader of the Norwegian Association of Pharmacists, Rønnaug Larsen, is happy to present the grant to Ragnhild Haugse.
Photo: Tore Rasmussen Steien/Norsk Farmaceutisk Tidsskrift

The grant is administered by the The Norwegian Association of Pharmacists, and its purpose is to encourage research within immunology, cancer and cardiovascular diseases and is to be distributed to pharmacists who conduct research from PhD level.

The basic hypothesis of sonoporation was that it provided improved drug delivery in cells by forming pores in cell membranes, but these mechanisms are today considered as much more complex. Ragnhild's research aims to give a better understanding of the effect of sonoporation and determine which ultrasound parameters and microbubble types and doses that show the best efficacy.

Read more in article in Farmatid.no (in Norwegian).

We look forward to seeing more of Ragnhild's work!

BOSTON SUMMER SCHOOL

Three CCBIO students are soon off to Boston as summer interns in the CCBIO-Harvard INTPART collaboration, more specifically in the The Vascular Biology Program which is situated in the Longwood Medical Area in Boston, and affiliated to Boston Children's Hospital and Harvard Medical School.


Amalie


Ridhima


Hanna

These are Amalie Fagerli Tegnander, medical student affiliated to Elisabeth Wik's group, Ridhima Das, PhD candidate in Dana Costea's group, and Hanna Dillekås, PhD candidate in Oddbjørn Straume's group.

Amalie will be working in Dr. Randy Watnick's laboratory. As a first year medical student, Amalie is very excited to get the chance to be in a large research group, learn lab techniques, build her network and hopefully contribute to the research performed.
Ridhima will be located to Dr. Diane Bielenberg's lab, mainly working with oral cancer in neuropilin 2 knockout mice.
Hanna is assigned to Dr. Michael Rogers' lab and will be studying genes regulating angiogenesis controlled tumor dormancy. She hopes to familiarize herself with molecular biology techniques such as CRISPR and the interpretation of angiogenic switch experiments and the transition from dormant to proliferative tumor.

See also report from last year's summer interns.

DOCTORAL DEFENSES

Maria Lie Lotsberg defended Monday April 29th 2019 her doctoral dissertation "The role of AXL and the microenvironment in cancer cell plasticity and therapy responses. A study in non-small cell lung cancer models" at the University of Bergen. Main supervisor was Professor James B. Lorens and co-supervisors were Professor Lars A. Akslen and Researcher Agnete S.T. Engelsen.
See press release (in Norwegian).

Sahba Shafiee defends Thursday June 20th 2019 at 13:15 in the Auditorium, Armauer Hansens Hus, Haukelandsveien 28, her doctoral dissertation "Translational Development of Preclinical Models and Therapies in Myelodysplastic Syndromes (MDS)". Main supervisor is Professor Emmet McCormack and co-supervisors are Associate Professor Astrid Olsnes Kittang and Professor Bjørn Tore Gjertsen.
See announcement.

Kjersti Tefre Davidsen defends Friday June 21st 2019 at 11:15 in Auditorium 1, BB building, Jonas Lies vei 91 her doctoral dissertation "The Receptor Tyrosine Kinase Axl in Tumour Phenotyptic Plasticity and Acquired Resistance to Cancer Targeted- and Immunotherapy". Main supervisor is Professor James Lorens and co-supervisor is Professor Oddbjørn Straume. See announcement.

CCBIO ANNUAL REPORT 2018

The most recent CCBIO Annual Report is now available, where you can read all about CCBIO's research, activities, events, statistics, personnel overview and much more.

It was published in time for the CCBIO Annual Symposium and was available there, but if you did not get one, you can download it as pdf from this website. If you prefer the paper version, visit us at the CCBIO offices and get one, or ask us to send you one.

Visiting address: Sentralblokka 2nd floor (hospital main building), Haukeland University Hospital.

COMING CCBIO EVENTS

Make sure to save the dates in your calendar, and register when applicable. You can see all planned CCBIO events in the CCBIO web calendar.

- June 18, CCBIO Special Seminar, Marine bioactive compounds as a source for new anticancer drugs
- June 20, CCBIO doctoral defense, Sahba Shafiee
- June 21, CCBIO doctoral defense, Kjersti Tefre Davidsen
- August 29, CCBIO Seminar, speaker tba
- August 29-September 3, CCBIO-VBP INTPART meeting, Reykjavik.
- September 19, CCBIO Junior Scientist Symposium
- September 26, CCBIO Seminar, speaker tba
- October 3-4, CCBIO course "Clinical Trials in Cancer Research", Bergen
- October 23-24, the 4th Scandinavian Symposium in Translational Pathology, Bergen (Solstrand)
- October 31, CCBIO Seminar, speaker tba
- November 7, CCBIO Junior Scientist Symposium
- November 28, CCBIO Seminar, speaker tba
- December 12, CCBIO Seminar, speaker tba
- December 9-13, CCBIO903 Cancer research: Ethical, economic and social aspects, Bergen

OTHER COMING EVENTS

- June 19, How to write competetive applications for ERC Starting and Consolidator Grants, UiB, Bergen. Registration deadline June 14th.
- June 26-29, 51st Meeting of the European Pancreatic Club, Bergen. The major European scientific forum in the field of pancreatology, presenting hot topics in basic and clinical pancreatology with a focus on translational aspects, including pancreas cancer.
- August 29-30, NorDoc PhD Summit, Århus. UiB is a member of NorDoc. This year's conference "From PhD programme to job market: Identify your real world skills" provides the opportunity for the candidates to present a poster on their own PhD project. Ragistration within June 23rd.
- August to November, University Library courses in EndNote, PubMed, Embase and systematic overviews, for UiB and Helse Bergen staff and students.
- August 15, the Arendal Week: OCC breakfast meeting on the future of cancer treatments, Arendal.
- September 5-6, Digital Life 2019, annual biotechnology research and innovation conference, Tromsø. Event from Centre of Digital Life Norway. Participation requires membership, which CCBIO PhD students and postdocs will be granted, and which also entitles you to apply for grants to cover travel and accommodation expenses.
- September 23-26, 'Pic' up your game - How to make those figures rock your science, Trondheim, Centre of Digital Life Norway. Participation requires membership, which CCBIO PhD students and postdocs will be granted.
- November 11. EHIN, conference on e-health in Norway, Oslo.

PUBLICATIONS

You can find the CCBIO publications on this pubmed link.
See the last 5 below.

- Røsland GV, Dyrstad SE, Tusubira D, Helwa R, Tan TZ, Lotsberg ML, Pettersen IKN, Berg A, Kindt C, Hoel F, Jacobsen K, Arason AJ, Engelsen AST, Ditzel HJ, Lønning PE, **Krakstad C**, Thiery JP, **Lorens JB**, Knappskog S, Tronstad KJ. Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of *SDHC*. Cancer Metab. 2019 Jun 1;7:6. eCollection 2019.
- Zeltz C, Alam J, Liu H, Erusappan PM, Hoschuetzky H, Molven A, Parajuli H, Cukierman E, **Costea DE**, Lu N, **Gullberg D**. α11β1 Integrin is Induced in a Subset of Cancer-Associated Fibroblasts in Desmoplastic Tumor Stroma and Mediates In Vitro Cell Migration. Cancers (Basel). 2019 Jun 1;11(6). pii: E765.
- Landolt L, Furriol J, Babickova J, Ahmed L, Eikrem Ø, Skogstrand T, Scherer A, Suliman S, Leh S, **Lorens JB**, Gausdal G, Marti HP, Osman T. AXL targeting reduces fibrosis development in experimental unilateral ureteral obstruction. Physiol Rep. 2019 May;7(10):e14091.
- Forthun RB, Hellesøy M, Sulen A, Kopperud RK, Sjøholt G, Bruserud Ø, **McCormack E**, **Gjertsen BT**. Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia. J Cancer Res Clin Oncol. 2019 May 20. [Epub ahead of print]
- Basnet S, Sharma S, **Costea DE**, Sapkota D. Expression profile and functional role of S100A14 in human cancer. Oncotarget. 2019 Apr 26;10(31):2996-3012. eCollection 2019 Apr 26. Review.

RECENT CCBIO IN THE MEDIA

Recent media appearances by CCBIO PIs and group members. For all media hits, see CCBIO's web pages.

03.06.19, Dagens Medisin, "Eggstokk-kreft: – Vil ha stor betydning hvis man kan spare pasienten for cellegift", Line Bjørge.

29.05.19, Farmatid.no, "Farmaceutene gir 300 000 til forskning på kreft og hjerneslag", Ragnhild Haugse.

28.05.19, På Høyden, "Verdensledende kreft-forsker besøkte UiB", Donald Gullberg.

16.05.19, Forskerforum, "Forskningsrådet lagar plan for open forsking", Roger Strand.

14.05.19, HollandBIO, "DCprime presents comprehensive preclinical results supporting lead clinical candidate DCP-001", 7th CCBIO Annual Symposium.

09.05.19, Forskning.no, "Fant ikke mer brystkreft med 3D-mammografi", Lars A. Akslen.

09.05.19, Helse Bergen, "3D-mammografi: Mer treffsikkert, men fant ikke mer kreft", Lars A. Akslen.

08.05.19, Forskerforum, "Lagar plan for open forsking", Roger Strand.

24.04.19, På Høyden, "Christieprisen til Jan Einar Greve", Lars A. Akslen.

22.04.19, Khrono, "162 nye navn som skal styre pengestrømmen til forskning", Inge Jonassen.

15.04.19, På Høyden, "Disse skal sitte i Forskningsråds-styrer", Inge Jonassen.

12.04.19, Forskerforum, "Disse skal avgjøre om du får støtte fra Forskningsrådet", Inge Jonassen.

10.04.19, Khrono, "Fra høgskole til universitet: Fare for kvasiakademisering av profesjoner", Roger Strand.